5.22
price up icon3.16%   0.16
after-market 시간 외 거래: 5.19 -0.03 -0.57%
loading

Immuneering Corp 주식(IMRX)의 최신 뉴스

pulisher
Aug 14, 2026

IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff? - Stocktwits

Aug 14, 2026
pulisher
Aug 14, 2026

Immuneering Stock Price Forecast. Should You Buy IMRX? - StockInvest.us

Aug 14, 2026
pulisher
Aug 10, 2026

HC Wainwright Estimates Immuneering Q3 Earnings - marketbeat.com

Aug 10, 2026
pulisher
Aug 06, 2026

Immuneering (NASDAQ:IMRX) Now Covered by HC Wainwright - MarketBeat

Aug 06, 2026
pulisher
Aug 06, 2026

Immuneering (NASDAQ:IMRX) Rating Increased to Strong-Buy at Chardan Capital - MarketBeat

Aug 06, 2026
pulisher
Aug 06, 2026

H.C. Wainwright initiates Immuneering stock coverage with buy rating - Investing.com

Aug 06, 2026
pulisher
Aug 06, 2026

H.C. Wainwright initiates Immuneering stock coverage with buy rating By Investing.com - Investing.com India

Aug 06, 2026
pulisher
Aug 06, 2026

This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Sahm

Aug 06, 2026
pulisher
Aug 05, 2026

Immuneering (NASDAQ:IMRX) Releases Earnings Results - MarketBeat

Aug 05, 2026
pulisher
Aug 05, 2026

Immuneering Corp 2026: Revenue ($17.44M), Net income ($17.27M), EPS ($0.27) — 10-Q Summary - TradingView

Aug 05, 2026
pulisher
Aug 05, 2026

Immuneering Q2 Loss Widens as Cash Runway Extends Into 2029 - Quiver Quantitative

Aug 05, 2026
pulisher
Aug 05, 2026

Immuneering reports Q2 2026 net loss $17.3M, cash $182.7M with runway into 2029 - TradingView

Aug 05, 2026
pulisher
Aug 05, 2026

Immuneering Reports 17.3-Month Median Overall Survival in First-Line Pancreatic Cancer and Progresses Phase 3 MAPKeeper 301 Trial - quiverquant.com

Aug 05, 2026
pulisher
Aug 05, 2026

Immuneering Corporation Q2 Net Income USD -17 - moomoo.com

Aug 05, 2026
pulisher
Aug 05, 2026

Immuneering reports strong pancreatic cancer tr... - Pluang

Aug 05, 2026
pulisher
Jul 30, 2026

IMRX|Immuneering Corp|Price:4.165|Chg%:+0.035 - TradingKey

Jul 30, 2026
pulisher
Jul 27, 2026

Immuneering Corp (IMRX) Income Statement - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Immuneering Corp (IMRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Immuneering Corp (IMRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Immuneering Corp (IMRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Immuneering Corp (IMRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Immuneering Corp (IMRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Immuneering Corp (IMRX) Institutional Confidence - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

IMRX|Immuneering Corp|Price:4.355|Chg%:+0.035 - TradingKey

Jul 27, 2026
pulisher
Jul 26, 2026

Immuneering Corp (IMRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jul 26, 2026
pulisher
Jul 26, 2026

Immuneering Corp (IMRX) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jul 26, 2026
pulisher
Jul 26, 2026

Immuneering Corporation (NASDAQ:IMRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Jul 26, 2026
pulisher
Jul 25, 2026

Immuneering Corp (IMRX) Cash Flow - TradingKey

Jul 25, 2026
pulisher
Jul 22, 2026

Stock Ratings | Morgan Stanley raised its target price for Intel (INTC) to $75; Maxim Group initiated coverage on Rein Therapeutics (RNTX) with a target price of $4, representing a potential gain of 373.93%. - Sahm

Jul 22, 2026
pulisher
Jul 22, 2026

Immuneering Corporation (IMRX) Stock Price, News, Quote & History - Yahoo! Finance Canada

Jul 22, 2026
pulisher
Jul 21, 2026

Immuneering reports preclinical data on atebimetinib in journal - Investing.com

Jul 21, 2026
pulisher
Jul 20, 2026

IMRX Maintains by Needham -- Price Target Raised to $18.00 - GuruFocus

Jul 20, 2026
pulisher
Jul 20, 2026

Immuneering (NASDAQ:IMRX) Downgraded to "Sell" Rating by Wall Street Zen - marketbeat.com

Jul 20, 2026
pulisher
Jul 18, 2026

Immuneering Corporation Announces Grants of Inducement Awards - The Manila Times

Jul 18, 2026
pulisher
Jul 17, 2026

Form 4 Immuneering Corp For: 17 July By Investing.com - Investing.com Nigeria

Jul 17, 2026
pulisher
Jul 17, 2026

IMRX News | IMMUNEERING CORPCLASS A (NASDAQ:IMRX) - ChartMill

Jul 17, 2026
pulisher
Jul 17, 2026

Immuneering (IMRX) awards CFO Andrew Gengos 650,000 stock options - Stock Titan

Jul 17, 2026
pulisher
Jul 17, 2026

Immuneering Corporation Announces Inducement Equity Grants to New CFO and Employee - Quiver Quantitative

Jul 17, 2026
pulisher
Jul 17, 2026

Immuneering’s New CFO Gets 650,000-Share Option With $4.78 Exercise Price - Stock Titan

Jul 17, 2026
pulisher
Jul 16, 2026

Immuneering Corp (IMRX) CFO discloses 225,000 Class A shares - Stock Titan

Jul 16, 2026
pulisher
Jul 15, 2026

Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Jul 15, 2026
pulisher
Jul 08, 2026

Cantor Fitzgerald initiates Immuneering stock with overweight rating - Investing.com

Jul 08, 2026
pulisher
Jul 03, 2026

If You Invested $1,000 in Immuneering Corp (IMRX) - Stock Titan

Jul 03, 2026
pulisher
Jul 03, 2026

IMRXImmuneering Corp Latest SEC Filings - Finviz

Jul 03, 2026
pulisher
Jun 30, 2026

Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth - Sahm

Jun 30, 2026
pulisher
Jun 27, 2026

Immuneering Corporation (IMRX) Surges 5% as Stock Approaches Key Resistance LevelBull Pennant - dars.gov.et

Jun 27, 2026
pulisher
Jun 26, 2026

Immuneering Corp. Class A Actuals & Estimates (NASDAQ:IMRX) - TradingView

Jun 26, 2026
pulisher
Jun 25, 2026

IMRX Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026
pulisher
Jun 25, 2026

Form 4 Immuneering Corp For: 24 June By Investing.com - Investing.com Nigeria

Jun 25, 2026
pulisher
Jun 24, 2026

Immuneering CEO Zeskind buys $10,948 in stock - Investing.com UK

Jun 24, 2026
pulisher
Jun 24, 2026

Immuneering CEO Zeskind buys $10,948 in stock By Investing.com - Investing.com India

Jun 24, 2026
pulisher
Jun 24, 2026

Immuneering CEO buys 2,400 shares in open market | IMRX Insider Trading - Stock Titan

Jun 24, 2026
pulisher
Jun 18, 2026

Immuneering Corp (IMRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jun 18, 2026
pulisher
Jun 17, 2026

Insider Buying: Brett Hall Acquires Additional Shares of Immunee - GuruFocus

Jun 17, 2026
pulisher
Jun 16, 2026

Immuneering (NASDAQ: IMRX) CSO purchases 6,035 shares in open-market trade - Stock Titan

Jun 16, 2026
$64.46
price up icon 1.80%
$36.24
price up icon 0.11%
$59.45
price up icon 1.45%
$128.32
price up icon 3.70%
$224.60
price down icon 1.77%
ONC ONC
$362.51
price up icon 4.33%
자본화:     |  볼륨(24시간):